Repligen | RGEN - Selling And Administration Expenses


Repligen reported $73.66M in Selling and Administration Expenses for its fiscal quarter ending in September of 2025.





Selling And Administration Expenses Change Date
Agilent USD 428M 37M Sep/2025
Align Technology USD 417.8M 30.89M Sep/2025
Bio Techne USD 116.21M 80.43M Sep/2025
BioMarin Pharmaceutical USD 223.42M 8.86M Sep/2025
Bristol-Myers Squibb USD 1.79B 76M Sep/2025
Bruker USD 242.5M 11.1M Sep/2025
Charles River Laboratories USD 177.59M 8.23M Sep/2025
Danaher USD 2.03B 35M Dec/2025
Dentsply International USD 355M 21M Sep/2025
Exact Sciences USD 491.64M 35.94M Sep/2025
General Electric Aerospace USD 1.58B 385M Dec/2025
Henry Schein USD 760M 17M Sep/2025
Illumina USD 256M 59M Sep/2025
IQVIA Holdings USD 514M 5M Sep/2025
Mettler Toledo International USD 248.39M 1.09M Sep/2025
Myriad Genetics USD 129M 1.3M Sep/2025
Pfizer USD 3.19B 209M Sep/2025
Repligen USD 73.66M 2.43M Sep/2025
Revvity USD 241.91M 9.6M Sep/2025
Standard Biotools USD 26.6M 1.5M Sep/2025
Thermo Fisher Scientific USD 1.98B 182M Dec/2025
Waters USD 214.23M 12.97M Sep/2025
West Pharmaceutical Services USD 102.7M 6.8M Sep/2025